Given the variable prevalence of DDR gene mutations across ethnic groups, including lower BRCA2 and ATM mutation rates reported in early-stage Asian PCa, further investigation is warranted to assess the clinical relevance of DDR status in guiding PSMA-targeted RLT across diverse populations [9, 10]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.